小鼠急性髓系白血病体内全基因组CRISPR筛选揭示微环境依赖性
研究在两种由KMT2A/MLLT3融合或Hoxa9与Meis1共表达驱动的小鼠急性髓系白血病(AML)模型中开展体内全基因组CRISPR筛选,并通过聚焦文库二次验证鉴定出72个体内白血病生长特异性必需基因,包括主要组织相容性复合体I类复合体组分、Cd47、补体受体Cr1l及β-4-半乳糖基化通路;部分体内特异性命中基因在人类AML病例中具有预后意义或为蛋白活性主调控因子,如整合素信号主调控因子Fermt3。
要点
- 体内全基因组CRISPR筛选鉴定出72个AML体内生长特异性必需基因。
- 命中基因包括MHC I类复合体组分、Cd47、Cr1l及β-4-半乳糖基化通路。
- Fermt3为整合素信号主调控因子,具体内特异性依赖与高预后相关性。
核心结论
- 研究建立了AML体内全基因组功能筛选的实验与计算流程,并提供了体内白血病生长必需驱动基因的全基因组资源。
研究设计与样本
- 在两种小鼠AML模型中开展体内全基因组CRISPR筛选:一种由KMT2A/MLLT3融合驱动,另一种由Hoxa9与Meis1组成性共表达驱动。
- 利用聚焦文库进行二次验证,鉴定体内白血病生长特异性必需基因。
主要发现
- 二次验证鉴定出72个体内白血病生长特异性必需基因,包括主要组织相容性复合体I类复合体组分、Cd47、补体受体Cr1l和β-4-半乳糖基化通路。
- 部分体内特异性命中基因在人类AML病例中具有预后效应或被推断为蛋白活性主调控因子。
- Fermt3为整合素信号主调控因子,被鉴定为具有体内特异性依赖且高预后相关性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Genome-wide CRISPR screens have been extremely useful in identifying therapeutic targets in diverse cancers by defining genes that are essential for malignant growth. However, most CRISPR screens were performed in vitro and thus cannot identify genes that are essential for interactions with the microenvironment in vivo. Here, we report genome-wide CRISPR screens in 2 in vivo murine models of acute myeloid leukemia (AML) driven by the KMT2A/MLLT3 fusion or by the constitutive coexpression of Hoxa9 and Meis1. Secondary validation using a focused library identified 72 genes specifically essential for leukemic growth in vivo, including components of the major histocompatibility complex class I complex, Cd47, complement receptor Cr1l, and the β-4-galactosylation pathway. Importantly, several of these in vivo-specific hits have a prognostic effect or are inferred to be master regulators of protein activity in human AML cases. For instance, we identified Fermt3, a master regulator of integrin signaling, as having in vivo-specific dependency with high prognostic relevance. Overall, we show an experimental and computational pipeline for genome-wide functional screens in vivo in AML and provide a genome-wide resource of essential drivers of leukemic growth in vivo.
引用
- Mercier FE, Shi J, Sykes DB, et al. In vivo genome-wide CRISPR screening in murine acute myeloid leukemia uncovers microenvironmental dependencies. Blood Adv. 2022. PMID: 35793392. doi:10.1182/bloodadvances.2022007250
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。